Velodyne Lidar Introduces Velabit™
7.1.2020 23:00:00 EET | Business Wire | Press release
Velodyne Lidar, Inc. today introduced Velabit™, Velodyne’s smallest sensor which brings new levels of versatility and affordability to 3D lidar perception, at CES 2020. The Velabit leverages Velodyne’s innovative lidar technology and manufacturing partnerships for cost optimization and high-volume production. The sensor advances Velodyne’s mission to make high-quality 3D lidar sensors readily accessible to everyone.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200107005849/en/
Velabit™, Velodyne Lidar’s smallest sensor, brings new levels of versatility and affordability to 3D lidar perception. (Photo: Velodyne Lidar)
The Velabit perfectly complements Velodyne’s sensor portfolio. The sensor delivers the same technology and performance found on Velodyne’s full suite of state-of-the-art sensors and will be the catalyst for creating endless possibilities for new applications in a variety of industries. The compact Velabit can be embedded almost anywhere within vehicles, robots, unmanned aerial vehicles (UAVs), infrastructure and more. It is designed to be easy to manufacture at mass production levels.
The Velabit is engineered to be an optimal automotive grade lidar solution for Advanced Driver Assistance Systems (ADAS) and autonomous vehicles. It enables robust perception coverage for Blind-Spot Monitoring, Cross Traffic Detection, Automatic Emergency Braking, and Pedestrian and Bicyclist Safety. Highly configurable for customer application, this mid-range sensor can be combined with other Velodyne lidar sensors, such as the Velarray™, for high-speed operation or function as a standalone lidar solution in low-speed applications.
The Velabit addresses the cost, safety and design challenges of autonomous solutions while delivering strong sensor performance. Here are the Velabit’s leading features:
- Integrated processing in a compact size of 2.4” x 2.4” x 1.38” – smaller than a deck of playing cards – to be easily embedded in a wide range of solutions.
- Range up to 100 meters.
- Outstanding field of view (FoV): 60-degree horizontal FoV x 10-degree vertical FoV.
- Highly configurable to support a range of applications.
- Proven, Class 1 eye-safe 903 nanometer technology.
- Bottom connector with cable length options.
- Multiple manufacturing sources scheduled to be available for qualified production projects.
“The Velabit democratizes lidar with its ultra-small form factor and its sensor pricing targeted at $100 in high-volume production, making 3D lidar available for all safety-critical applications,” said Anand Gopalan, Chief Executive Officer, Velodyne Lidar. “Its combination of performance, size and price position the Velabit to drive a quantum leap in the number of lidar-powered applications. The sensor delivers what the industry has been seeking: a breakthrough innovation that can jump-start a new era of autonomous solutions on a global scale.”
“Before the Velabit there was no suitable small and lightweight lidar for small unmanned aerial vehicles and unmanned ground vehicles performing obstacle avoidance or mapping,” said Alberto Lacaze, president, Robotic Research. “Since Robotic Research’s Pegasus Mini™ is a fully autonomous ground and air vehicle, it requires the Velabit’s size and versatility. In addition, the Velabit enables the most advanced GPS-denied HD mapping in the industry. The Velabit fills a much-needed space in the market and is currently in a class of its own.”
The Velabit will be available to customers mid-2020. Velodyne provides world-class technical support for the sensor across North America, Europe and Asia. It is now on display at Velodyne Lidar’s CES 2020 booth located at the Las Vegas Convention Center North Hall – booth #7520.
About Velodyne Lidar
Velodyne provides smart, powerful lidar solutions for autonomy and driver assistance. Headquartered in San Jose, Calif., Velodyne is known worldwide for its portfolio of breakthrough lidar sensor technologies. Velodyne’s Founder, David Hall, invented real-time surround view lidar systems in 2005 as part of Velodyne Acoustics. Mr. Hall’s invention revolutionized perception and autonomy for automotive, new mobility, mapping, robotics, and security. Velodyne’s high-performance product line includes a broad range of sensing solutions, including the cost-effective Puck™, the versatile Ultra Puck™, the autonomy-advancing Alpha Prime™, the ADAS-optimized Velarray™ and the groundbreaking software for driver assistance, Vella™.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200107005849/en/
Contact information
Sean Dowdall
Landis Communications Inc. for Velodyne Lidar, Inc.
(415)
286-7121
velodyne@landispr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
